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A B S T R A C T
Background
Complications of the third stage of labour are a significant cause of maternal mortality worldwide.
Objectives
To examine the effect of oxytocin given prophylactically in the third stage of labour on maternal and neonatal outcomes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (December 2004). We updated this search on 1 October
2009 and added the results to the awaiting classification section.
Selection criteria
Randomised or quasi-randomised controlled trials including pregnant women anticipating a vaginal delivery where oxytocin was given
prophylactically for the third stage of labour.
Data collection and analysis
The review authors independently assessed trial quality and extracted data. Analysis was by intention to treat. Subgroup analyses
were based on extent of selection bias, oxytocin in the context of active or expectant management of the third stage, and timing of
administration. Results are presented as relative risks, and weighted mean difference, both with 95% confidence intervals using a fixed-
effect model.
Main results
Fourteen trials are included.
In seven trials involving over 3000 women, prophylactic oxytocin showed benefits (reduced blood loss (relative risk (RR) for blood loss
greater than 500 ml 0.50; 95% confidence interval (CI) 0.43 to 0.59) and need for therapeutic oxytocics (RR 0.50; 95% CI 0.39 to
0.64) compared to no uterotonics.
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In six trials involving over 2800 women, there was little evidence of differential effects for oxytocin versus ergot alkaloids, except that
oxytocin was associated with fewer manual removals of the placenta (RR 0.57; 95% CI 0.41 to 0.79), and with the suggestion of less
raised blood pressure (RR 0.53; 95% CI 0.19 to 1.52) than with ergot alkaloids.
In five trials involving over 2800 women, there was little evidence of a synergistic effect of adding oxytocin to ergometrine versus
ergometrine alone.
Authors’ conclusions
Oxytocin appears to be beneficial for the prevention of postpartum haemorrhage. However, there is insufficient information about
other outcomes and side-effects hence it is difficult to be confident about the trade-offs for these benefits. There seems little evidence
in favour of ergot alkaloids alone compared to either oxytocin alone, or to ergometrine-oxytocin, but the data are sparse. More trials
are needed in domiciliary deliveries in developing countries, which shoulder most of the burden of third stage complications.
[Note: The ten citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]
P L A I N L A N G U A G E S U M M A R Y
Prophylactic oxytocin for the third stage of labour
Oxytocin used routinely after birth can reduce blood loss, but more research is needed on possible adverse effects.
The third stage of labour is that period from birth of the baby until delivery of the placenta. The degree of blood loss depends on how
quickly the placenta separates from the uterine wall and the uterine muscle contracts. Severe blood loss - postpartum haemorrhage, is
a major problem, particularly where there is poor nutrition and lack of access to treatment. The review of trials found routine use of
oxytocin, a drug which helps the uterus contract, may reduce the amount of blood loss, but there is not enough evidence about adverse
effects. More research is needed.
B A C K G R O U N D
The most reliable estimates of global mortality for mothers in
childbirth are reported as between 500,000 and 600,000 annually
(UNICEF 1996; WHO 1990). Many of these deaths result from
complications of the third stage of labour.
The third stage of labour is that period from delivery of the baby
until delivery of the placenta. After delivery of the baby and ces-
sation of umbilical cord pulsation the placenta separates from the
uterinewall through the spongy lining of thewomb (decidua spon-
giosa) and is delivered through the birth canal. The placenta sep-
arates as a result of capillary haemorrhage and the shearing effect
of uterine muscle contraction. The degree of blood loss associated
with placental separation and delivery depends on how quickly
the placenta separates from the uterine wall and how effectively
uterine muscle contracts around the placental bed (where the pla-
centa is attached to the wall of the uterus), and the blood vessels,
during and after separation, and expels the placenta through the
birth canal.
Moderate loss of blood is physiological and unlikely to lead to
later problems except for women who are already anaemic. The
major complication associated with this stage is postpartum haem-
orrhage (PPH). This is not necessarily torrential bleeding, and is
usually defined as bleeding from the genital tract of 500ml ormore
in the first 24 hours following delivery of the baby. Alternative
cut-off points of 600 ml (Beischer 1986) and 1000 ml (Burchell
1980) have also been suggested, and it has long been recognised
that such clinical estimation is likely to underestimate the actual
volume of blood lost by 34% to 50% (Newton 1961). This may
in part explain the variation in estimated incidence of PPH be-
tween 5% and 18% (Hall 1985; Gilbert 1987; Prendiville 1988a),
even within a single country like the UK, where PPH remains an
important cause of maternal mortality (DoH 2004; Hall 1985;
Gilbert 1987). Effects on maternal morbidity are less well docu-
mented, but are likely to include such inter-related outcomes as
anaemia, fatigue and depression.
Nearly all maternal deaths (99%) occur in the developing world
(Kwast 1991), where other factors, such as infection (especially
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HIV infection), poor nutritional status and lack of easy access to
treatment, may contribute to death in the presence of severe post-
partum haemorrhage. Many more women survive and suffer seri-
ous illness as a result, not only from the effects of acute anaemia
but also from the interventions which a severe haemorrhage may
necessitate (such as general anaesthesia, manual removal of the
placenta, blood transfusion, hysterectomy). Other aspects of the
management of labour such as induction and augmentation of
labour, or the duration of the second stage in the context of epidu-
ral anaesthesia may also have relevance for the third stage. Reduc-
ing the likelihood of postpartum haemorrhage by avoiding the use
of birth chairs in the second stage (Crowley 1991) could play a
part in reducing maternal morbidity and mortality.
This review concentrates on components of such management in
the third stage of labour. One component may be uterotonic drugs
which increase the tone of the uterine muscles. These uterotonics
were initially introduced for the treatment of PPH. Moir (Moir
1932) showed that ergometrine was the active principle on which
the known uterotonic effect of ergot had depended. Reviewing its
use in obstetric practice by the early 1950s, his opinion was that
“Fewdrugs can have become so firmly established in so short a time
and few drugs can be so completely indispensable as ergometrine is
now” (Moir 1955). Ergometrine (ergonovine in the United States)
became popular for routine management in the early 1950s. Oxy-
tocin is a naturally occurring uterotonic, which Du Vigneaud et al
synthesised and reported in 1953 (Du Vigneaud 1953). Embrey
et al (Embrey 1963) reported advantages of combining this with
ergometrine (as Syntometrine - oxytocin five international units
plus ergometrine 0.5 mg). In order to prevent blood loss, these
uterotonics and, more recently, prostaglandins are also being used
for prophylactic third stage management.
While few would dispute the contribution of uterotonic drugs in
the treatment of PPH, their role in routine prophylaxis is less clear.
This review considers the prophylactic role of one of these utero-
tonics, oxytocin, in the third stage of labour. Other relevant pub-
lished reviews are by Prendiville 2000, which compare active with
expectant third stage management (where active management in-
volves the package of interconnected interventions of prophylactic
uterotonics, early cutting and clamping of the umbilical cord, and
controlled cord traction); Gülmezoglu 2004 andMcDonald 2004,
which both consider the role of different prophylactic uterotonics
(prostaglandins, and ergometrine-oxytocin compared to oxytocin,
respectively) in third stage management; and Carroli 2001 look-
ing at the role of umbilical vein injection for the treatment of re-
tained placenta. Subsequent third stage management reviews will
consider the role of prophylactic uterotonics more generally, and
of prophylactic ergot alkaloids particularly. As these interventions
are very inter-related, some aspects of the role of oxytocin may be
found in these other reviews (e.g. Prendiville 2000; Gülmezoglu
2004; McDonald 2004).
O B J E C T I V E S
The objective of this review is to examine the effect of oxytocin
given prophylactically in the third stage of labour, defined as that
period from birth of the baby until delivery of the placenta, on
outcomes such as maternal blood loss and the length of the third
stage of labour, other effects on the mother, and the outcome for
the newborn baby. The objectives of this review will consider the
following comparisons:
1. oxytocin versus no uterotonics;
2. oxytocin versus ergot alkaloids;
3. oxytocin plus ergometrine versus ergot alkaloids.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All acceptably randomised or quasi-randomised controlled trials
were considered for inclusion, with exclusions on quality grounds
if there was potential for significant selection bias after trial entry.
Types of participants
All trials including pregnant women anticipating a vaginal deliv-
ery were considered, regardless of other aspects of third stage man-
agement.
Types of interventions
Oxytocin given prophylactically for the third stage of labour, at
whatever dose. The current review concentrates on oxytocin given
by injection, usually into a maternal vein or a muscle. The role
of prophylactic prostaglandins or ergot alkaloids, and uterotonics
given through the umbilical vein, or for the treatment of blood loss
or retained placenta, will be the subject of other reviews and are
not included here. Similarly, endogenous oxytocin (nipple stimu-
lation) is not included in this review.
Types of outcome measures
• Postpartum haemorrhage (PPH) (reported estimates of
blood loss greater than or equal to 500 ml)
• Severe PPH (clinically estimated blood loss greater than or
equal to 1000 ml)
• Mean blood loss (ml)
• Maternal haemoglobin concentration (Hb) less than 9 gm/
decilitre 24 to 48 hours postpartum
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• Blood transfusion
• Iron tablets during the puerperium
• Therapeutic uterotonics
• Third stage greater than 20 minutes
• Third stage greater than 40 minutes
• Mean length of third stage (minutes)
• Manual removal of the placenta
• Subsequent surgical evacuation of retained products of
conception
• Diastolic blood pressure greater than 100 mmHg between
delivery of baby and discharge from the labour ward
• Vomiting between delivery of baby and discharge from the
labour ward
• Nausea between delivery of baby and discharge from the
labour ward
• Headache between delivery of baby and discharge from the
labour ward
• Maternal pain during third stage of labour
• Maternal dissatisfaction with third stage management
• Secondary PPH (after 24 hours and before six weeks)
• Bleeding needing readmission or antibiotics
• Maternal fatigue at six weeks
• Apgar score less than seven at five minutes
• Admission to special care baby unit
• Jaundice (as defined by the authors)
• Not breastfeeding at discharge from hospital
• Not breastfeeding at six weeks
Search methods for identification of studies
Electronic searches
We searched theCochrane Pregnancy andChildbirthGroupTrials
Register by contacting the Trials Search Co-ordinator (December
2004). We updated this search on 1 October 2009 and added the
results to Studies awaiting classification.
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Data collection and analysis
For the first publication, two review authors checked the titles and
abstracts identified from the search. Two of the review authors ob-
tained the full text of all studies of possible relevance for indepen-
dent assessment. The methodological quality of the studies was
assessed with particular concentration on allocation concealment,
ranked using the Cochrane approach of adequate, uncertain or in-
adequate. Two review authors performed the data extraction. Trial
authors were contacted for clarification where relevant. Analysis
was by intention to treat.
For this update the following methods were used.
Selection of studies
We assessed for inclusion all potential studies we identified as a
result of the search strategy.We resolved any disagreement through
discussion.
Assessment of methodological quality of included
studies
We assessed the validity of each study using the criteria outlined
in the Cochrane Reviewers’ Handbook (Alderson 2004).
(1) Selection bias (randomisation and allocation
concealment)
We planned to assign a quality score for each trial, using the fol-
lowing criteria:
(A) adequate concealment of allocation, such as telephone ran-
domisation, consecutively numbered sealed opaque envelopes;
(B) unclear whether adequate concealment of allocation; such as
list or table used, sealed envelopes, or study does not report any
concealment approach;
(C) inadequate concealment of allocation, such as open list of
random number tables, use of case record numbers, dates of birth
or days of the week.
(2) Performance bias (blinding of participants, researchers
and outcome assessment)
We planned to assess blinding using the following criteria:
(A) blinding of participants (yes/no/unclear);
(B) blinding of caregiver (yes/no/unclear);
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(C) blinding of outcome assessment (yes/no/unclear).
(3) Attrition bias (loss of participants, e.g. withdrawals,
dropouts, protocol deviations)
Weplanned to assess completeness to followupusing the following
criteria:
(A) less than 5% loss of participants;
(B) 5% to 10% loss of participants;
(C) more than 10% and less than 20% loss of participants;
(D) more than 20% loss of participants.
Data extraction and management
We planned for all three review authors to extract the data and
to resolve discrepancies through discussion. We planned to use
the ReviewManager software (RevMan 2003) to double-enter the
data.
Measures of treatment effect
We planned to carry out statistical analysis using the ReviewMan-
ager software (RevMan 2003) and would have used a fixed-effect
meta-analysis for combining data if trials were sufficiently similar.
For dichotomous data: we planned to present results as summary
relative risk with 95% confidence intervals.
For continuous data: we planned to use the weighted mean differ-
ence if outcomes were measured in the same way between trials.
We planned to use the standardised mean difference to combine
trials that measured the same outcome, but used different meth-
ods. If there was evidence of skewness this would have been re-
ported.
We planned to analyse data on an intention-to-treat basis. There-
fore, all participants with available data would have been included
in the analysis in the group to which theywere allocated, regardless
of whether or not they received the allocated intervention. If in
the original reports participants were not analysed in the group to
which they were randomised, and there was sufficient information
in the trial report, we would have attempted to restore them to
the correct group.
Assessment of heterogeneity
Tests of heterogeneity between trials would have been applied if
appropriate using the I² statistic. If we identified high levels of
heterogeneity among the trials, (exceeding 50%), we would have
explored it by prespecified subgroup analysis and have performed
sensitivity analysis. A random-effects meta-analysis would have
been used as an overall summary if considered appropriate.
Three comparisons would have been considered:
(a) oxytocin versus no uterotonics;
(b) oxytocin versus ergot alkaloids;
(c) oxytocin plus ergometrine versus ergot alkaloids.
Subgroup analyses were planned based on extent of control for
selection bias, on whether the oxytocin is administered within the
context of active or expectant management of the third stage of
labour, and on the timing of administration. Further subgroup
analyses may consider the effects of different doses or different
routes of administration if appropriate data become available.
Results are presented as relative risks for dichotomous data, and
weighted mean difference for continuous data, both with 95%
confidence intervals using a fixed-effect model. If sufficient het-
erogeneity existed, sensitivity analyses would have be performed.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Forty-six trials were identified as being potentially eligible for this
review. Twenty-nine of these trials were excluded because: oxytocin
was being compared to ergometrine-oxytocin (Docherty 1982;
Dumoulin 1981; Soriano 1995; Symes 1984; Yuen 1995); no
clinical outcome data were available (Hacker 1979; Muller 1996;
Vaughan Williams1974); very strong likelihood of selection bias
(Friedman 1957; Nieminen 1963; Stearn 1963; Thornton 1988);
comparison of oxytocin given by different routes or at different
times (Francis (1) 1965b;Huh 2000; Khan 1997; Thornton 1988;
Hoffman 2004; Jackson 2001; Porter 1991; Schaefer 2004) (see
Characteristics of excluded studies). The remaining 14 trials con-
ducted in hospital and/or developed country settings were in-
cluded in this review (seeCharacteristics of included studies). (Ten
reports from an updated search in October 2009 have been added
to Studies awaiting classification.)
Risk of bias in included studies
Comparison A: oxytocin versus no uterotonics
Eight trials are potentially included in this comparison (De Groot
1996; Howard 1964; Ilancheran 1990; McGinty 1956; Newton
1961; Nordstrom 1997; Pierre 1992; Poeschmann 1991), but
McGinty 1956 provides no usable data for this part of the review.
Four of the remaining seven had adequate allocation concealment
(De Groot 1996; Howard 1964; Nordstrom 1997; Poeschmann
1991).
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Comparison B: oxytocin versus ergot alkaloids
Six trials are included in this comparison (De Groot 1996; Fugo
1958; Howard 1964; Ilancheran 1990; McGinty 1956; Sorbe
1978). Three had adequate allocation concealment (De Groot
1996; Fugo 1958; Howard 1964).
Comparison C: oxytocin plus ergometrine versus
ergot alkaloids
Five trials are included in this comparison (Barbaro 1961; Bonham
1963; Francis (2) 1965a; Ilancheran 1990; Soiva 1964). Two
had adequate allocation concealment (Bonham 1963; Francis (2)
1965a).
Effects of interventions
Fourteen trials are included.
Comparison A: oxytocin versus no uterotonics
Over 3000 women were entered into the trials of this comparison.
There was considerable variation even within these seven trials.
For instance, the sample size ranged from 10 to 1000 women. The
oxytocin was given intramuscularly in three trials (DeGroot 1996;
Newton 1961; Poeschmann 1991), and intravenously in four trials
(Howard 1964; Ilancheran 1990; Nordstrom 1997; Pierre 1992).
The dose also varied from three international units (IU) (Howard
1964) to 5 IU (De Groot 1996; Pierre 1992; Poeschmann 1991)
to 10 IU (Nordstrom 1997). In the trial by Ilancheran 1990, the
only information given is that it was the ’standard dose’. The non-
oxytocin group was either ’nothing’ (Ilancheran 1990; Newton
1961; Pierre 1992) or a saline placebo (Howard 1964; Nordstrom
1997; Poeschmann 1991). In one trial (De Groot 1996), an oral
placebo was given to allow blinding with a third group given oral
ergometrine. In two trials, the oxytocin was given after placental
delivery (Howard 1964; Newton 1961). In two trials, the study
was carried out within the context of expectantmanagement of the
third stage of labour (De Groot 1996; Nordstrom 1997), and in
one within active management (Pierre 1992). For the remainder,
the context was unclear.
The data from these studies reveal some clear benefits to women
who received prophylactic oxytocin as part of the routine manage-
ment of the third stage of labour when compared to women who
did not receive a uterotonic. These benefits relate specifically to
indicators of blood loss such as postpartum haemorrhage (whether
greater than 500 ml (relative risk (RR) 0.50; 95% confidence in-
terval (CI) 0.43 to 0.59) or greater than 1000 ml (RR 0.61; 95%
CI 0.44 to 0.87)) and the need for therapeutic oxytocics (RR 0.50;
95%CI 0.39 to 0.64). This conclusion holds regardless of the pre-
specified stratifying factors detailed in the Methods section above,
although with wider confidence intervals as the numbers of trials
and therefore women is reduced. It is not feasible to comment on
a possible relationship with manual removal of the placenta or the
need for a blood transfusion. For all other outcomes in the review,
either there are no data or the number of adverse events is very
small, and so definite conclusions cannot be drawn.
Comparison B: oxytocin versus ergot alkaloids
Over 2800 women were entered into the trials of this compar-
ison. There was considerable variation even within these six tri-
als. For instance, the sample size ranged from 10 to over 1000
women. The oxytocin was given intramuscularly in only one trial
(DeGroot 1996), intravenously in four trials (Fugo 1958;Howard
1964; Ilancheran 1990; Sorbe 1978) and both intramuscularly
and intravenously in one trial (McGinty 1956). The dose also
varied from 2 IU (Fugo 1958), to 3 IU (Howard 1964) to 5 IU
(De Groot 1996) to 10 IU (McGinty 1956; Sorbe 1978). In the
trial by Ilancheran 1990, the only information given is that it was
the ’standard dose’. The ergot alkaloid arm was even more var-
ied, ranging from slightly different preparations - ergometrine/er-
gonovine (De Groot 1996; Fugo 1958; Ilancheran 1990;McGinty
1956; Sorbe 1978), methylergonovine maleate (Howard 1964),
and methergine (McGinty 1956); different doses - from 0.2 mg
(Howard 1964;McGinty 1956; Sorbe 1978), to 0.4mg (De Groot
1996), 4 mg (Fugo 1958), and the ’standard dose’ in Ilancheran
1990; and different routes - all intravenous except oral inDe Groot
1996. In one trial, the oxytocin was given after placental delivery
(Howard 1964), and in one trial, the study was carried out within
the context of expectant management of the third stage of labour
(De Groot 1996). For the remainder, the context was unclear.
Overall there is little evidence of differential effects of these two
oxytocics. There are only two exceptions to this picture: oxytocin
is associated with fewermanual removals of the placenta (RR 0.57;
95% CI 0.41 to 0.79), and with the suggestion of less raised blood
pressure (RR 0.53; 95% CI 0.19 to 1.52), than are ergot alkaloids.
For all other outcomes in the review, either there are no data or the
number of adverse events is very small, and so definite conclusions
cannot be drawn.
Comparison C: oxytocin plus ergometrine versus
ergot alkaloids
Over 2800 women were entered into the trials of this compari-
son. There was considerable variation even within these five tri-
als. For instance, the sample size ranged from 10 to over 1000
women. The ergometrine-oxytocin was generally given intramus-
cularly, although in one trial it was given intravenously (Ilancheran
1990). The dose was standard-one ampoule containing oxytocin
5 IU and ergometrine 0.5 mg. The ergot alkaloid arm was more
varied, ranging from slightly different preparations - ergometrine
(Bonham 1963; Francis (2) 1965a; Ilancheran 1990), ergometrine
maleate (Barbaro 1961), and methergine (Soiva 1964); different
doses - from 0.12 mg (Soiva 1964), to 0.5 mg (Bonham 1963;
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Francis (2) 1965a), 0.10 mg (Barbaro 1961), and the ’standard
dose’ in Ilancheran 1990; and different routes - intravenous in
Ilancheran 1990 and Soiva 1964, intramuscular in Bonham 1963
and Francis (2) 1965a, and both in Barbaro 1961. The oxytocics
were given before placental delivery in all the trials. Whether the
trial was carried out within the context of expectant or of active
management was usually unclear (although one (Bonham 1963)
was a factorial design in which the other factors were controlled
cord traction or maternal effort).
Overall, there is little evidence of a synergistic effect of adding
oxytocin to ergometrine alone, other than in terms of reducing
the rate of blood loss greater than 500 ml in the subgroup of well-
randomised trials (RR 0.44; 95% CI 0.20 to 0.94). For all other
outcomes in the review, either there are no data or the number of
adverse events is very small, and so definite conclusions cannot be
drawn.
D I S C U S S I O N
Overall, there are too few data available for many definite conclu-
sions to be drawn about the role of prophylactic oxytocin in the
third stage of labour. There are strong suggestions of benefit in
terms of postpartum haemorrhage, and the need for therapeutic
oxytocics, when compared to using no uterotonic, but without
sufficient information about other outcomes and side-effects, it
is difficult to be confident about the trade-offs for these benefits.
Indeed, there is a suggestion that the risk of manual removal of
the placenta may be increased, particularly within the context of
oxytocin without the other components of active management
(early cord clamping/cutting and controlled cord traction). There
seems little evidence in favour of ergot alkaloids alone compared
to either oxytocin alone, or to ergometrine-oxytocin, but the data
are sparse.
There were insufficient data to examine the role of different doses
or routes of administration.
Suggested implications of the findings for practice and research
are shown below.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Before making major changes to practice based on the current
review, further information from other reviews considering the
role of active management (Prendiville 2000), of prostaglandins
(Gülmezoglu 2004), and of ergot alkaloids (McDonald 2004)
needs to be taken into account.
Nevertheless, given the benefit of oxytocin in terms of reducing
postpartum haemorrhage and the need for therapeutic oxytocics,
when compared to using no uterotonic, there appears to be a clear
practice implication in favour of using oxytocin. This has to be
tempered, however, by the knowledge that there is insufficient
information about most other outcomes and side-effects, and that
all the trials were conducted in hospitals and/or developed country
settings.
Similarly, although the data are sparse, the balance of evidence
does not support the prophylactic use of ergot alkaloids alone (in
contrast to either oxytocin alone, or to ergometrine-oxytocin).
Implications for research
Domiciliary deliveries in developing countries shoulder the bur-
den of most of the major adverse effects of complications arising
from the management of the third stage of labour. In order to
improve this situation, especially where the routine management
is expectant, there is a need to conduct a trial to see whether active
management would be preferable in these settings. Prior to this,
there needs to be evidence aboutwhich formof activemanagement
might be most appropriate to consider. This implies the need for
a trial of alternative uterotonics such as the current World Health
Organization trial comparing oral misoprostol with oxytocin in
the context of full active management, and a trial to see whether all
the components of the full active management package are useful.
The optimal dosing of oxytocin and route of administration need
to be determined in addition to dispelling concerns of potential
side-effects. Delivery systems for oxytocin need to be addressed
especially in developing countries such as oxytocin delivery in the
prefilled Uniject injection device. These trials should address out-
comes which are of immediate relevance to the majority of post-
partum women such as fatigue, and the ability to care for their
babies.
[Note: The ten citations in the awaiting classification section of
the review may alter the conclusions of the review once assessed.]
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barbaro 1961
Methods ’No selection was made’.
Timing of randomisation not stated.
Not blinded.
Participants Women admitted for delivery in one of 2 obstetric units in hospital in Melbourne, Australia. Over 28
weeks
Interventions (1) Intramuscular SE505 (synthetic preparation-mixture of 5 units of syntocin and 0.5 mg ergometrine
maleate in 1 ml) given immediately after delivery of the baby (n = 300).
(2) Intravenous 0.5 mg ergometrine maleate given immediately after delivery of the baby + intramuscular
0.5 mg ergometrine maleate after delivery of placenta (n = 300).
Otherwise expectant 3rd stage management (?).
Outcomes Postpartum haemorrhage (> 600 ml); average blood loss 266 vs 219 ml (SD not given); average duration
of 3rd stage 16 vs 13 minutes (SD not given)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Bonham 1963
Methods Selection of drug was made by random numbers. Timing of randomisation not stated.
Not blinded.
Participants All vaginal deliveries April 1961 to October 1962 in hospital in London, except: multiple pregnancies,
previous PPH or manual removal, forceps and breech deliveries must be postrandomisation exclusions but
does not state howmany were randomised), parity 4 or more, induction or augmentation with syntocinon
Interventions (1) Intramuscular 0.5 mg ergometrine + 5 units synthetic oxytocin, given at crowning of the head (n =
391).
(2) Intramuscular 0.5 mg ergometrine, given at crowning of the head (n = 416).
[Third group of ergometrine + hyaluronidase not considered for this review.]
Women were also selected in random two-week groups to either controlled cord traction (n = 199 er-
gometrine + oxytocin vs 217 ergometrine alone) or maternal effort/fundal pressure (192 vs 199).
No information about timing of cord clamping/cutting.
Outcomes Primary postpartum haemorrhage (> 568 ml estimated by adding to measured quantity a figure for loss
on linen and swabs used for perineal repair); mean blood loss (154 vs 178 ml, SD not given); mean length
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Bonham 1963 (Continued)
of third stage (6.3 vs 6.2 mins, SD not given); prolonged third stage (> 30 minutes); manual removal of
placenta
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
De Groot 1996
Methods Hospital pharmacy supplied numbered boxes of tablets and ampoules according to computer-generated
randomisation list. Informed consent asked in early labour. Assigned before delivery of baby’s head.
Double-blind for oral ergometrine vs placebo and unblinded for ergometrine and/or placebo vs oxytocin.
Randomisation 1:2:2, oxytocin to ergometrine to placebo. Multicentre
Participants Two university hospitals, a midwifery school and independent midwives in and aroundNijmegen, Nether-
lands. Women expecting to deliver in one of these settings, and who did not develop following exclu-
sion criteria: refusal, cardiovascular disease/hypertension, multiple pregnancy, non-cephalic presentation,
polyhydramnios, tocolysis 2 hours prior to delivery, anticoagulant therapy, stillbirth, antepartum haem-
orrhage, chemical induction or augmentation (oxytocin, prostaglandins), instrumental/operative delivery
(some of these must have been postrandomisation exclusions), anaemia Hb < 6.8 mmol/L (timing not
stated), previous third stage complications.
Four of 371 women were assigned to the study erroneously (3 forceps, 1 augmentation) and were excluded
postrandomisation. Otherwise eligible women wishing a natural childbirth refused to enter the trial
(numbers not stated)
Interventions All three interventions given immediately after birth of baby:
(1) intramuscular 5 IU oxytocin;
(2) oral 0.4 mg ergometrine;
(3) oral placebo.
Other third stage management expectant (although no information given about timing of cord clamping/
cutting). When mother feels contractions or there are signs of separation, maternal effort encouraged,
adopting position to aid gravity. If necessary, flat hand on abdomen to act as brace to aid pushing. Re-
attempt if placenta does not deliver spontaneously. If haemorrhage, administer extra oxytocics and/or
controlled cord traction
Outcomes Mean blood loss (ml); PPH (>= 500 ml); severe PPH (>= 1000 ml) (blood loss measured gravimetrically
(fresh perineal pad under perineum to absorb blood or fluid; gauzes and pads collected until one hour
after delivery of placenta and weighed. 100 g increase in weight considered equivalent to 100 ml blood);
length of third stage (11 (range 4-90), 15 (2-90), 14 (3-55) in oxytocin, ergometrine and placebo groups
respectively. No information about whether mean or median, and SD not given); blood pressure 15, 30,
45 and 60 minutes after delivery of placenta, in institutional deliveries only (oral ergometrine showed no
significant elevation); use of further oxytocics; manual removal of placenta; transfusion
Notes
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De Groot 1996 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Francis (2) 1965a
Methods ’Ampoules used in rotation and participants were unselected’.
Blinded.
Participants Two maternity hospitals in Liverpool, UK.
All women expected to deliver except those in whom an abnormal third stage was anticipated (previous
PPH, instrumental or breech deliveries, twin pregnancies, antepartum haemorrhage, severe anaemia,
intravenous oxytocin for induction or augmentation)
Interventions (1) 1 ml intramuscular ergometrine-oxytocin (5 IU oxytocin + 0.5 mg per 1 ml ergometrine) after delivery
of baby and cord divided , AND 1 ml water after placental delivery (n = 171).
(2) 0.5 mg intramuscular ergometrine after delivery of baby and cord divided, AND 1 ml water after
placental delivery (n = 183).
(3) 1 ml intramuscular water after delivery of baby and cord divided, AND 0.5 mg intramuscular er-
gometrine after placental delivery (n = 167).
No information about controlled cord traction or timing of cord clamping, so not clear whether in context
of active or expectant management.
Comparison in review is between groups 1 and 2.
Outcomes Blood loss (average 4.9, 6.4, 7.0 in groups 1, 2 and 3 respectively - not clear whether mean or median
and no SD given); for the review, loss of > 20 oz has been taken as PPH; retained placenta
(> 20 minutes).
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Fugo 1958
Methods Numbered identical drug packages administered in rotation. Number meaningless to obstetrician.
Blinded.
Participants Women delivering in a hospital in Chicago, USA.
No details given of inclusion/exclusion criteria, but description of study participants showed that half had
labour over 8 hours, and 98% received some anaesthetic agent
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Fugo 1958 (Continued)
Interventions All administered intravenously in 2 ml with anterior shoulder.
(1) 2 IU pitocin (natural oxytocin) n = 168.
(2) 2 IU syntocinon (synthetic oxytocin) n = 156.
(3) 4 mg ergonovine 149.
(4) 80 mg U3772 (alpha, alpha diphenyl gamma dimethylamino N-methyl valeramide-HCl) n = 151.
No other information about management of third stage.
Comparison for review is groups 1 and 2 combined vs group 3.
No information about other aspects of third stage management
Outcomes Method of placental delivery (high % of manual removals for teaching purposes if haemorrhage or
undelivered within 10 minutes); length of third stage (not significantly different between groups but data
only given for those delivered spontaneously ie within 10 minutes); blood loss with placenta; (one hour
postpartum (?)average blood loss 50.2 vs 40.8 ml; no SDs given)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Howard 1964
Methods Participants randomly selected for one of the 3 study drugs. A double-blind technique was used. Vials
identical in appearance. Contents not known until completion of the study
Participants Women delivering vaginally in hospital in Iowa, USA between August 1962 and July 1963
Interventions Following placental delivery, slow intravenous 1 cc injection of
A. 0.9% sodium chloride (n = 475).
B. 0.2 mg methylergonovine maleate (n = 505).
C. 3.0 IU oxytocin (n = 479).
Comparisons in this review between C and A, and C and B.
No information about other aspects of third stage management
Outcomes Blood pressure 1, 2, 5, 10 and 40 minutes after placental delivery and then hourly for 4 hours; blood loss
as estimated by attending physician; further treatment for uterine atony
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Ilancheran 1990
Methods ’Consecutive participants divided equally into 4 subgroups, distribution being done on a random basis’
Participants Women in spontaneous labour between 38 and 42 weeks’ gestation with normal vertex deliveries in
hospital in Singapore. 17/20 were multigravid
Interventions A. No oxytocic in 3rd stage and three groups given intravenous uterotonic in ’standard’ doses with the
delivery of the anterior shoulder.
B. Oxytocin.
C. Ergometrine-oxytocin.
D. Ergometrine.
Comparisons for this review are: B vs A; B vs D; C vs D.
Outcomes Prostaglandin levels 5, 15b and 30 minutes after delivery (significant rise in all four groups but no
differences between the groups); postpartum haemorrhage
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
McGinty 1956
Methods ’Cases picked at random’.
Unblinded.
Participants All vaginally delivered under pudendal block and demorol/scopolamine, in hospital in United States of
America
Interventions Drug given at birth of anterior shoulder:
A. 1 cc normal saline intravenously (n = 50).
B. 0.2 mg methergine intravenously (n = 50).
C. 0.2 mg ergonovine intravenously (n = 50).
D. pitocin 5 IU each intravenously and intramuscularly (n = 50).
Comparisons for this review:
D vs A; D vs B and C.
No information about other aspects of third stage management
Outcomes Diastolic and systolic bloodpressure 5, 15 and60minutes after administration - although data not provided
for control group; estimated severe blood loss over 1000 mlmentioned for one women inmethergine series
and one in control group (not included in data tables as unlikely to have been systematically recorded)
Notes
Risk of bias
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McGinty 1956 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Newton 1961
Methods Alternate allocation not blinded.
Participants Hospital in USA. No antenatal complications, term, no likely complication of labour and delivery
Interventions A. 1 ml synthetic oxytocin intramuscularly after placental delivery (n = 50).
B. Control (n = 50).
No information about other aspects of third stage management
Outcomes Blood loss, blood pressure, need for therapeutic oxytocics.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Nordstrom 1997
Methods Double-blind randomised.
2 sets of ampoules prepared and numbered according to computer generated schedule. Contents unknown
to women or caregivers
Participants Hospital in Sweden.
Singleton cephalic vaginal deliveries.
Interventions 1 ml intravenous after delivery of baby. Passive (expectant) management of the placenta.
10 IU oxytocin.
Saline.
Outcomes Blood loss; additional oxytocin (data tables give methylergometrine; clarification about other oxytocics
sought from authors), Hb, blood transfusion; manual removal
Notes Additional oxytocin (data tables give methylergometrine; clarification about other oxytocics sought from
authors)
Risk of bias
Item Authors’ judgement Description
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Nordstrom 1997 (Continued)
Allocation concealment? Yes A - Adequate
Pierre 1992
Methods Leaflets marked from 1-1000 alternate allocation ’this made possible a control of selection bias at entry by
the authors as the order in the trial had the same chronology as the date and time of entry in the labour
ward’
Participants Women expecting to deliver vaginally in hospital in France. Only exclusions - breech, twins, APH, refusal
Interventions Active management of third stage with (n = 488) and without 5 IU IV oxytocin (n = 488) with the anterior
shoulder
Outcomes Blood loss; length of third stage, MRP, maternal side-effects
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Poeschmann 1991
Methods Hospital pharmacy supplied numbered boxes. Allocation of boxes was by order of entry to the labour
ward. A nurse not working in the labour room prepared the injection
Participants April 1986 -88, 2 hospitals in Netherlands.
Uncomplicated singleton term pregnancies in spontaneous labour with spontaneous vaginal deliveries and
Hobel score of less than 10
Interventions After birth of baby:
A. IM 5 IU oxytocin.
B. 500 micrograms sulprostone.
C. saline.
Comparison in this review is A vs C.
Not sure whether active or expectant as says 3rd stage managed conservatively (expectantly) but cord
clamped within 1 minute of birth
Outcomes Blood loss; need for additional oxytocics; length of third stage
Notes
Risk of bias
Item Authors’ judgement Description
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Poeschmann 1991 (Continued)
Allocation concealment? Yes A - Adequate
Soiva 1964
Methods Every third normal parturient.
Participants Hospital, Finland.
Spontaneous, singleton, cephalic.
Interventions Immediately after birth of baby.
No efforts to expel placenta during first contraction of third stage.
IV methergine 0.12-0.2 mg
IM ergometrine-oxytocin (IU oxytocin + 0.5 ergometrine).
Not clear whether rest of third stage managed actively or expectantly
Outcomes Blood loss; duration of third stage, retained placenta, complications, MRP
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Sorbe 1978
Methods Alternate - odd and even numbers of mothers’ hospital records.
Not blinded.
Participants Hospital in Sweden.
Interventions IV after delivery of anterior shoulder.
0.2 mg ergometrine.
10 IU oxytocin.
Not clear whether rest of third stage managed actively or expectantly
(historical (?) control group given no uterotonic not included in the comparison)
Outcomes Blood loss; MRP, placental separation time.
Notes
Risk of bias
Item Authors’ judgement Description
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Sorbe 1978 (Continued)
Allocation concealment? No C - Inadequate
APH: antepartum haemorrhage
Hb: haemoglobin
IM: intramuscular
IU: international units
IV: intravenous
MRP: manual removal of placenta
PPH: postpartum haemorrhage
SD: standard deviation
vs: versus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bader 2000 Comparison of oxytocin to acupuncture not the subject of this review
Boucher 2004 Comparison of intramuscular carbetocin to a 2 hour intravenous oxytocin infusion administered after
delivery of the fetus and placenta
Docherty 1982 Comparison of oxytocin to acupuncture not the subject of this review
Dumoulin 1981 Oxytocin (different doses) versus ergometrine-oxytocin (subject of separate review)
Francis (1) 1965b Excluded because ergometrine-oxytocin given after end of 2nd stage and ergometrine given after end of
third stage, so the comparison of the two drugs is inextricably confoundedwith the timing of administration
Friedman 1957 Likely to be considerable bias after entry to study as 27% of the 1221 were ’deleted from the study’ as
inadequate observations were obtained. No other reasons given, and no indication of whether these women
were missing in similar proportions from the five intervention groups
Gerstenfeld 2001 Comparison of oxytocin to misoprostol (subject of separate review)
Hacker 1979 Excluded because no clinical outcome date available except for information on blood pressure which is
only given as mean changes from baseline
Hoffman 2004 Comparison of oxytocin within the context of active versus expectant management (subject of seperate
review)
Huh 2000 Excluded as only different timing of administration.
Irons 1994 Comparison of nipple stimulation to ergometrine-oxytocin which is not a subject of this review
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(Continued)
Jackson 2001 Comparison of oxytocin administered before and after placental delivery so the only difference is timing
of administration
Khan 1997 Comparison of prophylactic oxytocin within context of active management vs oxytocin after placental
delivery within context of expectant management (subject of separate review by Prendiville et al: Active
versus expectant management of third stage of labour - see Prendiville 2000)
Kundodyiwa 2001 Comparison of oxytocin to misoprostol (subject of separate review)
Lokugamage 2001 Comparison of oxytocin to misoprostol (subject of separate review) and at caesarean section
Muller 1996 5 IU IV oxytocin with crowning of head and Brandt-Andrews vs expectant. Abstract only, in French and
German. No clinical data available from authors
Nieminen 1963 No details of how allocated ’women divided into three groups’ - methergine, OCM505, oxytocin
Parsons 2004 Comparison of oxytocin to misoprostol (subject of separate review)
Porter 1991 Only difference is different route of administration.
Ramirez 2001 Inadequate information available about randomization and available only as abstract
Schaefer 2004 Excluded as only difference is timing of administration.
Schemmer 2001 Comparison of oxytocin administered before and after placental delivery so the only difference is timing
of administration
Soriano 1995 Compares oxytocin to oxytocin plus ergometrine (subject of separate review)
Stearn 1963 Allocation was to two different consultants one of whom gave all patients ergometrine-oxytocin, and the
other to give ’normal’ cases ergometrine with hyalase and abnormal given IV ergometrine
Symes 1984 Compares oxytocin to oxytocin plus ergometrine.
No clinical outcomes (serum prolactin levels only).
Tessier 2000 Excluded as only different routes of administration.
Thornton 1988 Strong likelihood of post-entry bias as alternate allocation used for 65, but 40 were withdrawn 40 as did
not meet inclusion criteria, leaving 10 and 15 in trial comparing oxytocin vs no oxytocin within active
management. Primary outcome plasma oxytocin concentration
Vaughan Williams1974 Excluded because no clinical outcome data available.
Yuen 1995 Oxytocin versus ergometrine-oxytocin (subject of separate review)
IU: international unit
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IV: intravenous
vs: versus
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D A T A A N D A N A L Y S E S
Comparison 1. Oxytocin versus no uterotonics (all trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
6 3193 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.43, 0.59]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
4 2243 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.44, 0.87]
3 Mean blood loss (ml) 4 1373 Mean Difference (IV, Fixed, 95% CI) -101.93 [-134.89, -
68.97]
4 Maternal haemoglobin
concentration (Hb) < 9
gm/deciltre 24 to 48 hours
postpartum
1 943 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.36, 1.09]
5 Blood transfusion 2 1221 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.50, 3.39]
7 Therapeutic uterontonics 5 2327 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.39, 0.64]
10 Mean length of third stage
(minutes)
1 52 Mean Difference (IV, Fixed, 95% CI) -1.80 [-5.55, 1.95]
11 Manual removal of the placenta 4 2243 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.79, 1.73]
15 Nausea between delivery of the
baby and discharge from the
labour ward
1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.74]
Comparison 2. Oxytocin versus no uterotonics (randomised trials only)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
4 2213 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.51, 0.72]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
3 1273 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.49, 1.05]
3 Mean blood loss (ml) 3 1273 Mean Difference (IV, Fixed, 95% CI) -109.12 [-151.93, -
66.32]
4 Maternal haemoglobin
concentration (Hb) < 9
gm/deciltre 24 to 48 hours
postpartum
1 943 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.36, 1.09]
5 Blood transfusion 2 1221 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.50, 3.39]
7 Therapeutic uterontonics 4 2227 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.41, 0.69]
10 Mean length of third stage
(minutes)
1 52 Mean Difference (IV, Fixed, 95% CI) -1.80 [-5.55, 1.95]
11 Manual removal of the placenta 3 1273 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.82, 3.41]
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15 Nausea between delivery of the
baby and discharge from the
labour ward
1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.74]
Comparison 3. Oxytocin versus no uterotonics (active management only)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
1 970 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.21, 0.41]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
1 970 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.14, 0.77]
11 Manual removal of the placenta 1 970 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.62, 1.59]
Comparison 4. Oxytocin versus no uterotonics (expectant management only)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
2 1221 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.51, 0.73]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
2 1221 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.49, 1.07]
3 Mean blood loss (ml) 2 1221 Mean Difference (IV, Fixed, 95% CI) -83.58 [-118.01, -
49.14]
4 Maternal haemoglobin
concentration (Hb) < 9
gm/deciltre 24 to 48 hours
postpartum
1 943 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.36, 1.09]
5 Blood transfusion 2 1221 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.50, 3.39]
7 Therapeutic uterontonics 2 1221 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.48, 0.90]
11 Manual removal of the placenta 2 1221 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.82, 3.41]
Comparison 5. Oxytocin versus no uterotonics (given before placental delivery)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
5 2253 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.42, 0.58]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
4 2243 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.44, 0.87]
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3 Mean blood loss (ml) 3 1273 Mean Difference (IV, Fixed, 95% CI) -109.12 [-151.93, -
66.32]
4 Maternal haemoglobin
concentration (Hb) < 9
gm/deciltre 24 to 48 hours
postpartum
1 943 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.36, 1.09]
5 Blood transfusion 2 1221 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.50, 3.39]
7 Therapeutic uterontonics 3 1273 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.47, 0.87]
10 Mean length of third stage
(minutes)
1 52 Mean Difference (IV, Fixed, 95% CI) -1.80 [-5.55, 1.95]
11 Manual removal of the placenta 4 2243 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.79, 1.73]
15 Nausea between delivery of the
baby and discharge from the
labour ward
1 52 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.74]
Comparison 6. Oxytocin versus no uterotonics (given after placental delivery)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
1 940 Risk Ratio (M-H, Fixed, 95% CI) 0.6 [0.32, 1.12]
3 Mean blood loss (ml) 1 100 Mean Difference (IV, Fixed, 95% CI) 12.0 [-102.29, 126.
29]
7 Therapeutic uterontonics 2 1054 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.20, 0.50]
Comparison 7. Oxytocin versus ergot alkaloids (all trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
5 2719 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.70, 1.16]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
3 1746 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.56, 1.74]
3 Mean blood loss (ml) 2 1273 Mean Difference (IV, Fixed, 95% CI) -29.12 [-59.36, 1.
12]
5 Blood transfusion 1 224 Risk Ratio (M-H, Fixed, 95% CI) 3.74 [0.34, 40.64]
7 Therapeutic uterontonics 2 1208 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.67, 1.55]
8 Third stage > 20 minutes 1 473 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Third stage > 40 minutes 1 383 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Mean length of third stage
(minutes)
1 1049 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.65, 0.05]
11 Manual removal of the placenta 3 1746 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.41, 0.79]
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13 Diastolic blood pressure > 100
mmHg between delivery of the
baby and discharge from the
labour ward
1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.19, 1.52]
Comparison 8. Oxytocin versus ergot alkaloids (randomised trials only)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
3 1660 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.73, 1.47]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
2 697 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.45, 2.66]
3 Mean blood loss (ml) 1 224 Mean Difference (IV, Fixed, 95% CI) 23.0 [-91.86, 137.
86]
5 Blood transfusion 1 224 Risk Ratio (M-H, Fixed, 95% CI) 3.74 [0.34, 40.64]
7 Therapeutic uterontonics 2 1208 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.67, 1.55]
8 Third stage > 20 minutes 1 473 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Third stage > 40 minutes 1 473 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Manual removal of the placenta 2 697 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.49, 1.02]
Comparison 10. Oxytocin versus ergot alkaloids (expectant management only)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
1 224 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.59, 1.28]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.45, 2.66]
3 Mean blood loss (ml) 1 224 Mean Difference (IV, Fixed, 95% CI) 23.0 [-91.86, 137.
86]
5 Blood transfusion 1 224 Risk Ratio (M-H, Fixed, 95% CI) 3.74 [0.34, 40.64]
7 Therapeutic uterontonics 1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.67, 2.31]
11 Manual removal of the placenta 1 224 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.09, 10.16]
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Comparison 11. Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
4 1756 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.64, 1.08]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
3 1746 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.56, 1.74]
3 Mean blood loss (ml) 2 1273 Mean Difference (IV, Fixed, 95% CI) -29.12 [-59.36, 1.
12]
5 Blood transfusion 1 224 Risk Ratio (M-H, Fixed, 95% CI) 3.74 [0.34, 40.64]
7 Therapeutic uterontonics 1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.67, 2.31]
8 Third stage > 20 minutes 1 473 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Third stage > 40 minutes 1 473 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Mean length of third stage
(minutes)
1 1049 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.65, 0.05]
11 Manual removal of the placenta 3 1746 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.41, 0.79]
13 Diastolic blood pressure > 100
mmHg between delivery of the
baby and discharge from the
labour ward
1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.19, 1.52]
Comparison 12. Oxytocin versus ergot alkaloids (given after placental delivery)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
1 963 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [0.77, 3.96]
7 Therapeutic uterontonics 1 984 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.50, 1.56]
Comparison 13. Oxytocin + ergometrine versus ergot alkaloids alone (all trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
5 2891 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.90, 1.84]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
1 1120 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.40, 6.94]
5 Blood transfusion 1 1120 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.23, 2.24]
8 Third stage > 20 minutes 3 2281 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.67, 1.19]
11 Manual removal of the placenta 2 1927 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.48, 2.20]
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Comparison 14. Oxytocin + ergometrine versus ergot alkaloids alone (randomised trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
2 1161 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.20, 0.94]
8 Third stage > 20 minutes 1 354 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.34, 30.57]
Comparison 15. Oxytocin + ergometrine versus ergot alkaloids alone (active management)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
1 416 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.03, 1.85]
8 Third stage > 20 minutes 1 416 Risk Ratio (M-H, Fixed, 95% CI) 6.54 [0.79, 53.87]
11 Manual removal of the placenta 1 416 Risk Ratio (M-H, Fixed, 95% CI) 4.36 [0.49, 38.70]
Comparison 17. Oxytocin + ergometrine versus ergot alkaloids alone (given before placental delivery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PPH (clinically estimated blood
loss > or = 500 ml)
5 2891 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.90, 1.84]
2 Severe PPH (clinically estimated
blood loss > or = 1000 ml)
1 1120 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.40, 6.94]
5 Blood transfusion 1 1120 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.23, 2.24]
8 Third stage > 20 minutes 3 2281 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.67, 1.19]
11 Manual removal of the placenta 2 1927 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.48, 2.20]
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Analysis 1.1. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 1 PPH (clinically estimated
blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 55/143 10.2 % 0.83 [ 0.57, 1.22 ]
Howard 1964 15/470 25/470 6.6 % 0.60 [ 0.32, 1.12 ]
Ilancheran 1990 0/5 0/5 Not estimable
Nordstrom 1997 104/513 175/487 47.1 % 0.56 [ 0.46, 0.70 ]
Pierre 1992 37/488 126/482 33.3 % 0.29 [ 0.21, 0.41 ]
Poeschmann 1991 7/28 10/24 2.8 % 0.60 [ 0.27, 1.33 ]
Total (95% CI) 1582 1611 100.0 % 0.50 [ 0.43, 0.59 ]
Total events: 188 (Oxytocin), 391 (Control)
Heterogeneity: Chi2 = 18.10, df = 4 (P = 0.001); I2 =78%
Test for overall effect: Z = 8.76 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours Oxytocin Favours Control
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Analysis 1.2. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 2 Severe PPH (clinically
estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 16/143 14.2 % 0.80 [ 0.34, 1.87 ]
Nordstrom 1997 32/513 43/487 55.3 % 0.71 [ 0.45, 1.10 ]
Pierre 1992 7/488 21/482 26.5 % 0.33 [ 0.14, 0.77 ]
Poeschmann 1991 2/28 3/24 4.0 % 0.57 [ 0.10, 3.14 ]
Total (95% CI) 1107 1136 100.0 % 0.61 [ 0.44, 0.87 ]
Total events: 48 (Oxytocin), 83 (Control)
Heterogeneity: Chi2 = 2.86, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
0.1 0.2 0.5 1 2 5 10
Favours Oxytocin Favours Control
30Prophylactic oxytocin for the third stage of labour (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 3 Mean blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 143 520 (419) 7.3 % -21.00 [ -142.93, 100.93 ]
Newton 1961 50 345 (285) 50 333 (298) 8.3 % 12.00 [ -102.29, 126.29 ]
Nordstrom 1997 513 409 (3.45) 487 527 (412) 81.1 % -118.00 [ -154.59, -81.41 ]
Poeschmann 1991 28 374 (279) 24 548 (376) 3.3 % -174.00 [ -356.51, 8.51 ]
Total (95% CI) 669 704 100.0 % -101.93 [ -134.89, -68.97 ]
Heterogeneity: Chi2 = 6.85, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 6.06 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 4 Maternal haemoglobin
concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 4 Maternal haemoglobin concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nordstrom 1997 20/485 30/458 100.0 % 0.63 [ 0.36, 1.09 ]
Total (95% CI) 485 458 100.0 % 0.63 [ 0.36, 1.09 ]
Total events: 20 (Oxytocin), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.5. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 5 Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 3/143 29.2 % 1.22 [ 0.21, 7.16 ]
Nordstrom 1997 7/513 5/487 70.8 % 1.33 [ 0.42, 4.16 ]
Total (95% CI) 591 630 100.0 % 1.30 [ 0.50, 3.39 ]
Total events: 9 (Oxytocin), 8 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
0.1 0.2 0.5 1 2 5 10
Favours Oxytocin Favours Control
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Analysis 1.7. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 7 Therapeutic
uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 26/143 11.5 % 0.99 [ 0.55, 1.78 ]
Howard 1964 21/479 58/475 36.6 % 0.36 [ 0.22, 0.58 ]
Newton 1961 1/50 11/50 6.9 % 0.09 [ 0.01, 0.68 ]
Nordstrom 1997 40/513 67/487 43.2 % 0.57 [ 0.39, 0.82 ]
Poeschmann 1991 0/28 2/24 1.7 % 0.17 [ 0.01, 3.42 ]
Total (95% CI) 1148 1179 100.0 % 0.50 [ 0.39, 0.64 ]
Total events: 76 (Oxytocin), 164 (Control)
Heterogeneity: Chi2 = 10.64, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 5.33 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.10. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 10 Mean length of third
stage (minutes).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 10 Mean length of third stage (minutes)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Poeschmann 1991 28 9.9 (7.4) 24 11.7 (6.4) 100.0 % -1.80 [ -5.55, 1.95 ]
Total (95% CI) 28 24 100.0 % -1.80 [ -5.55, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 11 Manual removal of the
placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 0/143 0.8 % 5.47 [ 0.23, 132.66 ]
Nordstrom 1997 18/513 11/487 25.7 % 1.55 [ 0.74, 3.26 ]
Pierre 1992 32/488 32/482 73.4 % 0.99 [ 0.62, 1.59 ]
Poeschmann 1991 0/28 0/24 Not estimable
Total (95% CI) 1107 1136 100.0 % 1.17 [ 0.79, 1.73 ]
Total events: 51 (Oxytocin), 43 (Control)
Heterogeneity: Chi2 = 1.95, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
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Analysis 1.15. Comparison 1 Oxytocin versus no uterotonics (all trials), Outcome 15 Nausea between
delivery of the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 1 Oxytocin versus no uterotonics (all trials)
Outcome: 15 Nausea between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poeschmann 1991 0/28 1/24 100.0 % 0.29 [ 0.01, 6.74 ]
Total (95% CI) 28 24 100.0 % 0.29 [ 0.01, 6.74 ]
Total events: 0 (Oxytocin), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 2.1. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 1 PPH
(clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 55/143 15.3 % 0.83 [ 0.57, 1.22 ]
Howard 1964 15/470 25/470 9.8 % 0.60 [ 0.32, 1.12 ]
Nordstrom 1997 104/513 175/487 70.6 % 0.56 [ 0.46, 0.70 ]
Poeschmann 1991 7/28 10/24 4.2 % 0.60 [ 0.27, 1.33 ]
Total (95% CI) 1089 1124 100.0 % 0.61 [ 0.51, 0.72 ]
Total events: 151 (Oxytocin), 265 (Control)
Heterogeneity: Chi2 = 3.08, df = 3 (P = 0.38); I2 =3%
Test for overall effect: Z = 5.62 (P < 0.00001)
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Analysis 2.2. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 2 Severe
PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 16/143 19.3 % 0.80 [ 0.34, 1.87 ]
Nordstrom 1997 32/513 43/487 75.2 % 0.71 [ 0.45, 1.10 ]
Poeschmann 1991 2/28 3/24 5.5 % 0.57 [ 0.10, 3.14 ]
Total (95% CI) 619 654 100.0 % 0.72 [ 0.49, 1.05 ]
Total events: 41 (Oxytocin), 62 (Control)
Heterogeneity: Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
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Analysis 2.3. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 3 Mean
blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 143 520 (419) 12.3 % -21.00 [ -142.93, 100.93 ]
Nordstrom 1997 513 409 (345) 487 527 (412) 82.2 % -118.00 [ -165.23, -70.77 ]
Poeschmann 1991 28 374 (279) 24 548 (376) 5.5 % -174.00 [ -356.51, 8.51 ]
Total (95% CI) 619 654 100.0 % -109.12 [ -151.93, -66.32 ]
Heterogeneity: Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 5.00 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 4 Maternal
haemoglobin concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 4 Maternal haemoglobin concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nordstrom 1997 20/485 30/458 100.0 % 0.63 [ 0.36, 1.09 ]
Total (95% CI) 485 458 100.0 % 0.63 [ 0.36, 1.09 ]
Total events: 20 (Oxytocin), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
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Analysis 2.5. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 5 Blood
transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 3/143 29.2 % 1.22 [ 0.21, 7.16 ]
Nordstrom 1997 7/513 5/487 70.8 % 1.33 [ 0.42, 4.16 ]
Total (95% CI) 591 630 100.0 % 1.30 [ 0.50, 3.39 ]
Total events: 9 (Oxytocin), 8 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
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Analysis 2.7. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 26/143 12.4 % 0.99 [ 0.55, 1.78 ]
Howard 1964 21/479 58/475 39.3 % 0.36 [ 0.22, 0.58 ]
Nordstrom 1997 40/513 67/487 46.4 % 0.57 [ 0.39, 0.82 ]
Poeschmann 1991 0/28 2/24 1.8 % 0.17 [ 0.01, 3.42 ]
Total (95% CI) 1098 1129 100.0 % 0.53 [ 0.41, 0.69 ]
Total events: 75 (Oxytocin), 153 (Control)
Heterogeneity: Chi2 = 7.46, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 4.80 (P < 0.00001)
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Analysis 2.10. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 10 Mean
length of third stage (minutes).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 10 Mean length of third stage (minutes)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Poeschmann 1991 28 9.9 (7.4) 24 11.7 (6.4) 100.0 % -1.80 [ -5.55, 1.95 ]
Total (95% CI) 28 24 100.0 % -1.80 [ -5.55, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 11 Manual
removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 0/143 3.0 % 5.47 [ 0.23, 132.66 ]
Nordstrom 1997 18/513 11/487 97.0 % 1.55 [ 0.74, 3.26 ]
Poeschmann 1991 0/28 0/24 Not estimable
Total (95% CI) 619 654 100.0 % 1.67 [ 0.82, 3.41 ]
Total events: 19 (Oxytocin), 11 (Control)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 2.15. Comparison 2 Oxytocin versus no uterotonics (randomised trials only), Outcome 15 Nausea
between delivery of the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 2 Oxytocin versus no uterotonics (randomised trials only)
Outcome: 15 Nausea between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poeschmann 1991 0/28 1/24 100.0 % 0.29 [ 0.01, 6.74 ]
Total (95% CI) 28 24 100.0 % 0.29 [ 0.01, 6.74 ]
Total events: 0 (Oxytocin), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 3.1. Comparison 3 Oxytocin versus no uterotonics (active management only), Outcome 1 PPH
(clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 3 Oxytocin versus no uterotonics (active management only)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pierre 1992 37/488 126/482 100.0 % 0.29 [ 0.21, 0.41 ]
Total (95% CI) 488 482 100.0 % 0.29 [ 0.21, 0.41 ]
Total events: 37 (Oxytocin), 126 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 7.05 (P < 0.00001)
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Analysis 3.2. Comparison 3 Oxytocin versus no uterotonics (active management only), Outcome 2 Severe
PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 3 Oxytocin versus no uterotonics (active management only)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pierre 1992 7/488 21/482 100.0 % 0.33 [ 0.14, 0.77 ]
Total (95% CI) 488 482 100.0 % 0.33 [ 0.14, 0.77 ]
Total events: 7 (Oxytocin), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
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Analysis 3.11. Comparison 3 Oxytocin versus no uterotonics (active management only), Outcome 11
Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 3 Oxytocin versus no uterotonics (active management only)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pierre 1992 32/488 32/482 100.0 % 0.99 [ 0.62, 1.59 ]
Total (95% CI) 488 482 100.0 % 0.99 [ 0.62, 1.59 ]
Total events: 32 (Oxytocin), 32 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 4.1. Comparison 4 Oxytocin versus no uterotonics (expectant management only), Outcome 1
PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 4 Oxytocin versus no uterotonics (expectant management only)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 55/143 17.8 % 0.83 [ 0.57, 1.22 ]
Nordstrom 1997 104/513 175/487 82.2 % 0.56 [ 0.46, 0.70 ]
Total (95% CI) 591 630 100.0 % 0.61 [ 0.51, 0.73 ]
Total events: 129 (Oxytocin), 230 (Control)
Heterogeneity: Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 5.26 (P < 0.00001)
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Analysis 4.2. Comparison 4 Oxytocin versus no uterotonics (expectant management only), Outcome 2
Severe PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 4 Oxytocin versus no uterotonics (expectant management only)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 16/143 20.4 % 0.80 [ 0.34, 1.87 ]
Nordstrom 1997 32/513 43/487 79.6 % 0.71 [ 0.45, 1.10 ]
Total (95% CI) 591 630 100.0 % 0.73 [ 0.49, 1.07 ]
Total events: 39 (Oxytocin), 59 (Control)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
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Analysis 4.3. Comparison 4 Oxytocin versus no uterotonics (expectant management only), Outcome 3
Mean blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 4 Oxytocin versus no uterotonics (expectant management only)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 143 520 (419) 8.0 % -21.00 [ -142.93, 100.93 ]
Nordstrom 1997 513 270 (260) 487 359 (315) 92.0 % -89.00 [ -124.90, -53.10 ]
Total (95% CI) 591 630 100.0 % -83.58 [ -118.01, -49.14 ]
Heterogeneity: Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 4.76 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Oxytocin versus no uterotonics (expectant management only), Outcome 4
Maternal haemoglobin concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 4 Oxytocin versus no uterotonics (expectant management only)
Outcome: 4 Maternal haemoglobin concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nordstrom 1997 20/485 30/458 100.0 % 0.63 [ 0.36, 1.09 ]
Total (95% CI) 485 458 100.0 % 0.63 [ 0.36, 1.09 ]
Total events: 20 (Oxytocin), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
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Analysis 4.5. Comparison 4 Oxytocin versus no uterotonics (expectant management only), Outcome 5
Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 4 Oxytocin versus no uterotonics (expectant management only)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 3/143 29.2 % 1.22 [ 0.21, 7.16 ]
Nordstrom 1997 7/513 5/487 70.8 % 1.33 [ 0.42, 4.16 ]
Total (95% CI) 591 630 100.0 % 1.30 [ 0.50, 3.39 ]
Total events: 9 (Oxytocin), 8 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
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Analysis 4.7. Comparison 4 Oxytocin versus no uterotonics (expectant management only), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 4 Oxytocin versus no uterotonics (expectant management only)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 26/143 21.1 % 0.99 [ 0.55, 1.78 ]
Nordstrom 1997 40/513 67/487 78.9 % 0.57 [ 0.39, 0.82 ]
Total (95% CI) 591 630 100.0 % 0.66 [ 0.48, 0.90 ]
Total events: 54 (Oxytocin), 93 (Control)
Heterogeneity: Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 2.65 (P = 0.0080)
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Analysis 4.11. Comparison 4 Oxytocin versus no uterotonics (expectant management only), Outcome 11
Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 4 Oxytocin versus no uterotonics (expectant management only)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 0/143 3.0 % 5.47 [ 0.23, 132.66 ]
Nordstrom 1997 18/513 11/487 97.0 % 1.55 [ 0.74, 3.26 ]
Total (95% CI) 591 630 100.0 % 1.67 [ 0.82, 3.41 ]
Total events: 19 (Oxytocin), 11 (Control)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 5.1. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 1
PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 55/143 10.9 % 0.83 [ 0.57, 1.22 ]
Ilancheran 1990 0/5 0/5 Not estimable
Nordstrom 1997 104/513 175/487 50.4 % 0.56 [ 0.46, 0.70 ]
Pierre 1992 37/488 126/482 35.6 % 0.29 [ 0.21, 0.41 ]
Poeschmann 1991 7/28 10/24 3.0 % 0.60 [ 0.27, 1.33 ]
Total (95% CI) 1112 1141 100.0 % 0.50 [ 0.42, 0.58 ]
Total events: 173 (Oxytocin), 366 (Control)
Heterogeneity: Chi2 = 18.00, df = 3 (P = 0.00044); I2 =83%
Test for overall effect: Z = 8.67 (P < 0.00001)
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Analysis 5.2. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 2
Severe PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 16/143 14.2 % 0.80 [ 0.34, 1.87 ]
Nordstrom 1997 32/513 43/487 55.3 % 0.71 [ 0.45, 1.10 ]
Pierre 1992 7/488 21/482 26.5 % 0.33 [ 0.14, 0.77 ]
Poeschmann 1991 2/28 3/24 4.0 % 0.57 [ 0.10, 3.14 ]
Total (95% CI) 1107 1136 100.0 % 0.61 [ 0.44, 0.87 ]
Total events: 48 (Oxytocin), 83 (Control)
Heterogeneity: Chi2 = 2.86, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
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Analysis 5.3. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 3
Mean blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 143 520 (419) 12.3 % -21.00 [ -142.93, 100.93 ]
Nordstrom 1997 513 409 (345) 487 527 (412) 82.2 % -118.00 [ -165.23, -70.77 ]
Poeschmann 1991 28 374 (279) 24 548 (376) 5.5 % -174.00 [ -356.51, 8.51 ]
Total (95% CI) 619 654 100.0 % -109.12 [ -151.93, -66.32 ]
Heterogeneity: Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 5.00 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 4
Maternal haemoglobin concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 4 Maternal haemoglobin concentration (Hb) < 9 gm/deciltre 24 to 48 hours postpartum
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nordstrom 1997 20/485 30/458 100.0 % 0.63 [ 0.36, 1.09 ]
Total (95% CI) 485 458 100.0 % 0.63 [ 0.36, 1.09 ]
Total events: 20 (Oxytocin), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
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Analysis 5.5. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 5
Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 3/143 29.2 % 1.22 [ 0.21, 7.16 ]
Nordstrom 1997 7/513 5/487 70.8 % 1.33 [ 0.42, 4.16 ]
Total (95% CI) 591 630 100.0 % 1.30 [ 0.50, 3.39 ]
Total events: 9 (Oxytocin), 8 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
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Analysis 5.7. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 26/143 20.4 % 0.99 [ 0.55, 1.78 ]
Nordstrom 1997 40/513 67/487 76.6 % 0.57 [ 0.39, 0.82 ]
Poeschmann 1991 0/28 2/24 3.0 % 0.17 [ 0.01, 3.42 ]
Total (95% CI) 619 654 100.0 % 0.64 [ 0.47, 0.87 ]
Total events: 54 (Oxytocin), 95 (Control)
Heterogeneity: Chi2 = 3.23, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 2.81 (P = 0.0049)
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Analysis 5.10. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 10
Mean length of third stage (minutes).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 10 Mean length of third stage (minutes)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Poeschmann 1991 28 9.9 (7.4) 24 11.7 (6.4) 100.0 % -1.80 [ -5.55, 1.95 ]
Total (95% CI) 28 24 100.0 % -1.80 [ -5.55, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 5.11. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 11
Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 0/143 0.8 % 5.47 [ 0.23, 132.66 ]
Nordstrom 1997 18/513 11/487 25.7 % 1.55 [ 0.74, 3.26 ]
Pierre 1992 32/488 32/482 73.4 % 0.99 [ 0.62, 1.59 ]
Poeschmann 1991 0/28 0/24 Not estimable
Total (95% CI) 1107 1136 100.0 % 1.17 [ 0.79, 1.73 ]
Total events: 51 (Oxytocin), 43 (Control)
Heterogeneity: Chi2 = 1.95, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
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Analysis 5.15. Comparison 5 Oxytocin versus no uterotonics (given before placental delivery), Outcome 15
Nausea between delivery of the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 5 Oxytocin versus no uterotonics (given before placental delivery)
Outcome: 15 Nausea between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Poeschmann 1991 0/28 1/24 100.0 % 0.29 [ 0.01, 6.74 ]
Total (95% CI) 28 24 100.0 % 0.29 [ 0.01, 6.74 ]
Total events: 0 (Oxytocin), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 6.1. Comparison 6 Oxytocin versus no uterotonics (given after placental delivery), Outcome 1
PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 6 Oxytocin versus no uterotonics (given after placental delivery)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Howard 1964 15/470 25/470 100.0 % 0.60 [ 0.32, 1.12 ]
Total (95% CI) 470 470 100.0 % 0.60 [ 0.32, 1.12 ]
Total events: 15 (Oxytocin), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
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Analysis 6.3. Comparison 6 Oxytocin versus no uterotonics (given after placental delivery), Outcome 3
Mean blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 6 Oxytocin versus no uterotonics (given after placental delivery)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Newton 1961 50 345 (285) 50 333 (298) 100.0 % 12.00 [ -102.29, 126.29 ]
Total (95% CI) 50 50 100.0 % 12.00 [ -102.29, 126.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 6.7. Comparison 6 Oxytocin versus no uterotonics (given after placental delivery), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 6 Oxytocin versus no uterotonics (given after placental delivery)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Howard 1964 21/479 58/475 84.1 % 0.36 [ 0.22, 0.58 ]
Newton 1961 1/50 11/50 15.9 % 0.09 [ 0.01, 0.68 ]
Total (95% CI) 529 525 100.0 % 0.32 [ 0.20, 0.50 ]
Total events: 22 (Oxytocin), 69 (Control)
Heterogeneity: Chi2 = 1.74, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 4.85 (P < 0.00001)
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Analysis 7.1. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 1 PPH (clinically
estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 54/146 34.6 % 0.87 [ 0.59, 1.28 ]
Fugo 1958 0/324 0/149 Not estimable
Howard 1964 15/470 9/493 8.1 % 1.75 [ 0.77, 3.96 ]
Ilancheran 1990 0/5 1/5 1.4 % 0.33 [ 0.02, 6.65 ]
Sorbe 1978 48/506 63/543 55.9 % 0.82 [ 0.57, 1.17 ]
Total (95% CI) 1383 1336 100.0 % 0.90 [ 0.70, 1.16 ]
Total events: 88 (Oxytocin), 127 (Ergot Alkaloids)
Heterogeneity: Chi2 = 3.28, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 0.80 (P = 0.42)
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Analysis 7.2. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 2 Severe PPH (clinically
estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 12/146 36.6 % 1.09 [ 0.45, 2.66 ]
Fugo 1958 0/324 0/149 Not estimable
Sorbe 1978 13/506 15/543 63.4 % 0.93 [ 0.45, 1.94 ]
Total (95% CI) 908 838 100.0 % 0.99 [ 0.56, 1.74 ]
Total events: 20 (Oxytocin), 27 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 7.3. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 3 Mean blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 146 476 (340) 6.9 % 23.00 [ -91.86, 137.86 ]
Sorbe 1978 506 273 (247) 543 306 (271) 93.1 % -33.00 [ -64.35, -1.65 ]
Total (95% CI) 584 689 100.0 % -29.12 [ -59.36, 1.12 ]
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 5 Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 1/146 100.0 % 3.74 [ 0.34, 40.64 ]
Total (95% CI) 78 146 100.0 % 3.74 [ 0.34, 40.64 ]
Total events: 2 (Oxytocin), 1 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 7.7. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 7 Therapeutic
uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 21/146 37.5 % 1.25 [ 0.67, 2.31 ]
Howard 1964 21/479 25/505 62.5 % 0.89 [ 0.50, 1.56 ]
Total (95% CI) 557 651 100.0 % 1.02 [ 0.67, 1.55 ]
Total events: 35 (Oxytocin), 46 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 7.8. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 8 Third stage > 20 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 8 Third stage > 20 minutes
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fugo 1958 0/324 0/149 Not estimable
Total (95% CI) 324 149 Not estimable
Total events: 0 (Oxytocin), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.9. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 9 Third stage > 40 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 9 Third stage > 40 minutes
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fugo 1958 0/234 0/149 Not estimable
Total (95% CI) 234 149 Not estimable
Total events: 0 (Oxytocin), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.10. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 10 Mean length of third
stage (minutes).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 10 Mean length of third stage (minutes)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sorbe 1978 506 9.5 (7.1) 543 10.3 (6.9) 100.0 % -0.80 [ -1.65, 0.05 ]
Total (95% CI) 506 543 100.0 % -0.80 [ -1.65, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 7.11. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 11 Manual removal of the
placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 2/146 1.7 % 0.94 [ 0.09, 10.16 ]
Fugo 1958 55/324 36/149 60.5 % 0.70 [ 0.48, 1.02 ]
Sorbe 1978 10/506 32/543 37.8 % 0.34 [ 0.17, 0.68 ]
Total (95% CI) 908 838 100.0 % 0.57 [ 0.41, 0.79 ]
Total events: 66 (Oxytocin), 70 (Ergot Alkaloids)
Heterogeneity: Chi2 = 3.60, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 3.39 (P = 0.00069)
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Analysis 7.13. Comparison 7 Oxytocin versus ergot alkaloids (all trials), Outcome 13 Diastolic blood
pressure > 100 mm Hg between delivery of the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 7 Oxytocin versus ergot alkaloids (all trials)
Outcome: 13 Diastolic blood pressure > 100 mm Hg between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McGinty 1956 4/50 15/100 100.0 % 0.53 [ 0.19, 1.52 ]
Total (95% CI) 50 100 100.0 % 0.53 [ 0.19, 1.52 ]
Total events: 4 (Oxytocin), 15 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 8.1. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 1 PPH
(clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 54/146 81.1 % 0.87 [ 0.59, 1.28 ]
Fugo 1958 0/324 0/149 Not estimable
Howard 1964 15/470 9/493 18.9 % 1.75 [ 0.77, 3.96 ]
Total (95% CI) 872 788 100.0 % 1.03 [ 0.73, 1.47 ]
Total events: 40 (Oxytocin), 63 (Ergot Alkaloids)
Heterogeneity: Chi2 = 2.39, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.18 (P = 0.85)
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Analysis 8.2. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 2 Severe
PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 12/146 100.0 % 1.09 [ 0.45, 2.66 ]
Fugo 1958 0/324 0/149 Not estimable
Total (95% CI) 402 295 100.0 % 1.09 [ 0.45, 2.66 ]
Total events: 7 (Oxytocin), 12 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 8.3. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 3 Mean
blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 146 476 (340) 100.0 % 23.00 [ -91.86, 137.86 ]
Total (95% CI) 78 146 100.0 % 23.00 [ -91.86, 137.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 5 Blood
transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 1/146 100.0 % 3.74 [ 0.34, 40.64 ]
Total (95% CI) 78 146 100.0 % 3.74 [ 0.34, 40.64 ]
Total events: 2 (Oxytocin), 1 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 8.7. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 21/146 37.5 % 1.25 [ 0.67, 2.31 ]
Howard 1964 21/479 25/505 62.5 % 0.89 [ 0.50, 1.56 ]
Total (95% CI) 557 651 100.0 % 1.02 [ 0.67, 1.55 ]
Total events: 35 (Oxytocin), 46 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 8.8. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 8 Third
stage > 20 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 8 Third stage > 20 minutes
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fugo 1958 0/324 0/149 Not estimable
Total (95% CI) 324 149 Not estimable
Total events: 0 (Oxytocin), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 8.9. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 9 Third
stage > 40 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 9 Third stage > 40 minutes
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fugo 1958 0/324 0/149 Not estimable
Total (95% CI) 324 149 Not estimable
Total events: 0 (Oxytocin), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 8.11. Comparison 8 Oxytocin versus ergot alkaloids (randomised trials only), Outcome 11 Manual
removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 8 Oxytocin versus ergot alkaloids (randomised trials only)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 2/146 2.7 % 0.94 [ 0.09, 10.16 ]
Fugo 1958 55/324 36/149 97.3 % 0.70 [ 0.48, 1.02 ]
Total (95% CI) 402 295 100.0 % 0.71 [ 0.49, 1.02 ]
Total events: 56 (Oxytocin), 38 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
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Analysis 10.1. Comparison 10 Oxytocin versus ergot alkaloids (expectant management only), Outcome 1
PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 10 Oxytocin versus ergot alkaloids (expectant management only)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 54/146 100.0 % 0.87 [ 0.59, 1.28 ]
Total (95% CI) 78 146 100.0 % 0.87 [ 0.59, 1.28 ]
Total events: 25 (Oxytocin), 54 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.1 0.2 0.5 1 2 5 10
Favours Oxytocin Favours Ergots
65Prophylactic oxytocin for the third stage of labour (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.2. Comparison 10 Oxytocin versus ergot alkaloids (expectant management only), Outcome 2
Severe PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 10 Oxytocin versus ergot alkaloids (expectant management only)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 12/146 100.0 % 1.09 [ 0.45, 2.66 ]
Total (95% CI) 78 146 100.0 % 1.09 [ 0.45, 2.66 ]
Total events: 7 (Oxytocin), 12 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 10.3. Comparison 10 Oxytocin versus ergot alkaloids (expectant management only), Outcome 3
Mean blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 10 Oxytocin versus ergot alkaloids (expectant management only)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 146 476 (340) 100.0 % 23.00 [ -91.86, 137.86 ]
Total (95% CI) 78 146 100.0 % 23.00 [ -91.86, 137.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Oxytocin versus ergot alkaloids (expectant management only), Outcome 5
Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 10 Oxytocin versus ergot alkaloids (expectant management only)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 1/146 100.0 % 3.74 [ 0.34, 40.64 ]
Total (95% CI) 78 146 100.0 % 3.74 [ 0.34, 40.64 ]
Total events: 2 (Oxytocin), 1 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 10.7. Comparison 10 Oxytocin versus ergot alkaloids (expectant management only), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 10 Oxytocin versus ergot alkaloids (expectant management only)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 21/146 100.0 % 1.25 [ 0.67, 2.31 ]
Total (95% CI) 78 146 100.0 % 1.25 [ 0.67, 2.31 ]
Total events: 14 (Oxytocin), 21 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 10.11. Comparison 10 Oxytocin versus ergot alkaloids (expectant management only), Outcome 11
Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 10 Oxytocin versus ergot alkaloids (expectant management only)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 2/146 100.0 % 0.94 [ 0.09, 10.16 ]
Total (95% CI) 78 146 100.0 % 0.94 [ 0.09, 10.16 ]
Total events: 1 (Oxytocin), 2 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 11.1. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome 1
PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 25/78 54/146 37.7 % 0.87 [ 0.59, 1.28 ]
Fugo 1958 0/324 0/149 Not estimable
Ilancheran 1990 0/5 1/5 1.5 % 0.33 [ 0.02, 6.65 ]
Sorbe 1978 48/506 63/543 60.8 % 0.82 [ 0.57, 1.17 ]
Total (95% CI) 913 843 100.0 % 0.83 [ 0.64, 1.08 ]
Total events: 73 (Oxytocin), 118 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.41, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 11.2. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome 2
Severe PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 7/78 12/146 36.6 % 1.09 [ 0.45, 2.66 ]
Fugo 1958 0/324 0/149 Not estimable
Sorbe 1978 13/506 15/543 63.4 % 0.93 [ 0.45, 1.94 ]
Total (95% CI) 908 838 100.0 % 0.99 [ 0.56, 1.74 ]
Total events: 20 (Oxytocin), 27 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 11.3. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome 3
Mean blood loss (ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 3 Mean blood loss (ml)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
De Groot 1996 78 499 (454) 146 476 (340) 6.9 % 23.00 [ -91.86, 137.86 ]
Sorbe 1978 506 273 (247) 543 306 (271) 93.1 % -33.00 [ -64.35, -1.65 ]
Total (95% CI) 584 689 100.0 % -29.12 [ -59.36, 1.12 ]
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
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Analysis 11.5. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome 5
Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 5 Blood transfusion
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 2/78 1/146 100.0 % 3.74 [ 0.34, 40.64 ]
Total (95% CI) 78 146 100.0 % 3.74 [ 0.34, 40.64 ]
Total events: 2 (Oxytocin), 1 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 11.7. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 14/78 21/146 100.0 % 1.25 [ 0.67, 2.31 ]
Total (95% CI) 78 146 100.0 % 1.25 [ 0.67, 2.31 ]
Total events: 14 (Oxytocin), 21 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 11.8. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome 8
Third stage > 20 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 8 Third stage > 20 minutes
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fugo 1958 0/324 0/149 Not estimable
Total (95% CI) 324 149 Not estimable
Total events: 0 (Oxytocin), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.9. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome 9
Third stage > 40 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 9 Third stage > 40 minutes
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fugo 1958 0/324 0/149 Not estimable
Total (95% CI) 324 149 Not estimable
Total events: 0 (Oxytocin), 0 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.10. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome
10 Mean length of third stage (minutes).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 10 Mean length of third stage (minutes)
Study or subgroup Oxytocin Ergot Alkaloids
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sorbe 1978 506 9.5 (7.1) 543 10.3 (6.9) 100.0 % -0.80 [ -1.65, 0.05 ]
Total (95% CI) 506 543 100.0 % -0.80 [ -1.65, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 11.11. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome
11 Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 11 Manual removal of the placenta
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
De Groot 1996 1/78 2/146 1.7 % 0.94 [ 0.09, 10.16 ]
Fugo 1958 55/324 36/149 60.5 % 0.70 [ 0.48, 1.02 ]
Sorbe 1978 10/506 32/543 37.8 % 0.34 [ 0.17, 0.68 ]
Total (95% CI) 908 838 100.0 % 0.57 [ 0.41, 0.79 ]
Total events: 66 (Oxytocin), 70 (Ergot Alkaloids)
Heterogeneity: Chi2 = 3.60, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 3.39 (P = 0.00069)
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Analysis 11.13. Comparison 11 Oxytocin versus ergot alkaloids (given before placental delivery), Outcome
13 Diastolic blood pressure > 100 mm Hg between delivery of the baby and discharge from the labour ward.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 11 Oxytocin versus ergot alkaloids (given before placental delivery)
Outcome: 13 Diastolic blood pressure > 100 mm Hg between delivery of the baby and discharge from the labour ward
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McGinty 1956 4/50 15/100 100.0 % 0.53 [ 0.19, 1.52 ]
Total (95% CI) 50 100 100.0 % 0.53 [ 0.19, 1.52 ]
Total events: 4 (Oxytocin), 15 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 12.1. Comparison 12 Oxytocin versus ergot alkaloids (given after placental delivery), Outcome 1
PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 12 Oxytocin versus ergot alkaloids (given after placental delivery)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Howard 1964 15/470 9/493 100.0 % 1.75 [ 0.77, 3.96 ]
Total (95% CI) 470 493 100.0 % 1.75 [ 0.77, 3.96 ]
Total events: 15 (Oxytocin), 9 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 12.7. Comparison 12 Oxytocin versus ergot alkaloids (given after placental delivery), Outcome 7
Therapeutic uterontonics.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 12 Oxytocin versus ergot alkaloids (given after placental delivery)
Outcome: 7 Therapeutic uterontonics
Study or subgroup Oxytocin Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Howard 1964 21/479 25/505 100.0 % 0.89 [ 0.50, 1.56 ]
Total (95% CI) 479 505 100.0 % 0.89 [ 0.50, 1.56 ]
Total events: 21 (Oxytocin), 25 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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Analysis 13.1. Comparison 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials), Outcome 1
PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barbaro 1961 39/300 10/300 19.3 % 3.90 [ 1.98, 7.67 ]
Bonham 1963 5/391 13/416 24.3 % 0.41 [ 0.15, 1.14 ]
Francis (2) 1965a 4/171 9/183 16.8 % 0.48 [ 0.15, 1.52 ]
Ilancheran 1990 0/5 1/5 2.9 % 0.33 [ 0.02, 6.65 ]
Soiva 1964 18/560 19/560 36.7 % 0.95 [ 0.50, 1.79 ]
Total (95% CI) 1427 1464 100.0 % 1.29 [ 0.90, 1.84 ]
Total events: 66 (Syntometrine), 52 (Ergot Alkaloids)
Heterogeneity: Chi2 = 19.68, df = 4 (P = 0.00058); I2 =80%
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 13.2. Comparison 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials), Outcome 2
Severe PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials)
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Soiva 1964 5/560 3/560 100.0 % 1.67 [ 0.40, 6.94 ]
Total (95% CI) 560 560 100.0 % 1.67 [ 0.40, 6.94 ]
Total events: 5 (Syntometrine), 3 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
0.1 0.2 0.5 1 2 5 10
Favours Syntometrine Favours Ergots
75Prophylactic oxytocin for the third stage of labour (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 13.5. Comparison 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials), Outcome 5
Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials)
Outcome: 5 Blood transfusion
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Soiva 1964 5/560 7/560 100.0 % 0.71 [ 0.23, 2.24 ]
Total (95% CI) 560 560 100.0 % 0.71 [ 0.23, 2.24 ]
Total events: 5 (Syntometrine), 7 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
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Analysis 13.8. Comparison 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials), Outcome 8
Third stage > 20 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials)
Outcome: 8 Third stage > 20 minutes
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 10/391 7/416 7.6 % 1.52 [ 0.58, 3.95 ]
Francis (2) 1965a 3/171 1/183 1.1 % 3.21 [ 0.34, 30.57 ]
Soiva 1964 66/560 81/560 91.3 % 0.81 [ 0.60, 1.10 ]
Total (95% CI) 1122 1159 100.0 % 0.89 [ 0.67, 1.19 ]
Total events: 79 (Syntometrine), 89 (Ergot Alkaloids)
Heterogeneity: Chi2 = 2.78, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 13.11. Comparison 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials), Outcome
11 Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 13 Oxytocin + ergometrine versus ergot alkaloids alone (all trials)
Outcome: 11 Manual removal of the placenta
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 5/391 5/416 37.7 % 1.06 [ 0.31, 3.65 ]
Soiva 1964 8/560 8/560 62.3 % 1.00 [ 0.38, 2.65 ]
Total (95% CI) 951 976 100.0 % 1.02 [ 0.48, 2.20 ]
Total events: 13 (Syntometrine), 13 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 14.1. Comparison 14 Oxytocin + ergometrine versus ergot alkaloids alone (randomised trials),
Outcome 1 PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 14 Oxytocin + ergometrine versus ergot alkaloids alone (randomised trials)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 5/391 13/416 59.2 % 0.41 [ 0.15, 1.14 ]
Francis (2) 1965a 4/171 9/183 40.8 % 0.48 [ 0.15, 1.52 ]
Total (95% CI) 562 599 100.0 % 0.44 [ 0.20, 0.94 ]
Total events: 9 (Syntometrine), 22 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
0.1 0.2 0.5 1 2 5 10
Favours Syntometrine Favours Ergots
78Prophylactic oxytocin for the third stage of labour (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.8. Comparison 14 Oxytocin + ergometrine versus ergot alkaloids alone (randomised trials),
Outcome 8 Third stage > 20 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 14 Oxytocin + ergometrine versus ergot alkaloids alone (randomised trials)
Outcome: 8 Third stage > 20 minutes
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Francis (2) 1965a 3/171 1/183 100.0 % 3.21 [ 0.34, 30.57 ]
Total (95% CI) 171 183 100.0 % 3.21 [ 0.34, 30.57 ]
Total events: 3 (Syntometrine), 1 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
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Analysis 15.1. Comparison 15 Oxytocin + ergometrine versus ergot alkaloids alone (active management),
Outcome 1 PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 15 Oxytocin + ergometrine versus ergot alkaloids alone (active management)
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 1/199 5/217 100.0 % 0.22 [ 0.03, 1.85 ]
Total (95% CI) 199 217 100.0 % 0.22 [ 0.03, 1.85 ]
Total events: 1 (Syntometrine), 5 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 15.8. Comparison 15 Oxytocin + ergometrine versus ergot alkaloids alone (active management),
Outcome 8 Third stage > 20 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 15 Oxytocin + ergometrine versus ergot alkaloids alone (active management)
Outcome: 8 Third stage > 20 minutes
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 6/199 1/217 100.0 % 6.54 [ 0.79, 53.87 ]
Total (95% CI) 199 217 100.0 % 6.54 [ 0.79, 53.87 ]
Total events: 6 (Syntometrine), 1 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
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Analysis 15.11. Comparison 15 Oxytocin + ergometrine versus ergot alkaloids alone (active management),
Outcome 11 Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 15 Oxytocin + ergometrine versus ergot alkaloids alone (active management)
Outcome: 11 Manual removal of the placenta
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 4/199 1/217 100.0 % 4.36 [ 0.49, 38.70 ]
Total (95% CI) 199 217 100.0 % 4.36 [ 0.49, 38.70 ]
Total events: 4 (Syntometrine), 1 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 17.1. Comparison 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental
delivery, Outcome 1 PPH (clinically estimated blood loss > or = 500 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental delivery
Outcome: 1 PPH (clinically estimated blood loss > or = 500 ml)
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barbaro 1961 39/300 10/300 19.3 % 3.90 [ 1.98, 7.67 ]
Bonham 1963 5/391 13/416 24.3 % 0.41 [ 0.15, 1.14 ]
Francis (2) 1965a 4/171 9/183 16.8 % 0.48 [ 0.15, 1.52 ]
Ilancheran 1990 0/5 1/5 2.9 % 0.33 [ 0.02, 6.65 ]
Soiva 1964 18/560 19/560 36.7 % 0.95 [ 0.50, 1.79 ]
Total (95% CI) 1427 1464 100.0 % 1.29 [ 0.90, 1.84 ]
Total events: 66 (Syntometrine), 52 (Ergot Alkaloids)
Heterogeneity: Chi2 = 19.68, df = 4 (P = 0.00058); I2 =80%
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 17.2. Comparison 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental
delivery, Outcome 2 Severe PPH (clinically estimated blood loss > or = 1000 ml).
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental delivery
Outcome: 2 Severe PPH (clinically estimated blood loss > or = 1000 ml)
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Soiva 1964 5/560 3/560 100.0 % 1.67 [ 0.40, 6.94 ]
Total (95% CI) 560 560 100.0 % 1.67 [ 0.40, 6.94 ]
Total events: 5 (Syntometrine), 3 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 17.5. Comparison 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental
delivery, Outcome 5 Blood transfusion.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental delivery
Outcome: 5 Blood transfusion
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Soiva 1964 5/560 7/560 100.0 % 0.71 [ 0.23, 2.24 ]
Total (95% CI) 560 560 100.0 % 0.71 [ 0.23, 2.24 ]
Total events: 5 (Syntometrine), 7 (Ergot Alkaloids)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
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Analysis 17.8. Comparison 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental
delivery, Outcome 8 Third stage > 20 minutes.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental delivery
Outcome: 8 Third stage > 20 minutes
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 10/391 7/416 7.6 % 1.52 [ 0.58, 3.95 ]
Francis (2) 1965a 3/171 1/183 1.1 % 3.21 [ 0.34, 30.57 ]
Soiva 1964 66/560 81/560 91.3 % 0.81 [ 0.60, 1.10 ]
Total (95% CI) 1122 1159 100.0 % 0.89 [ 0.67, 1.19 ]
Total events: 79 (Syntometrine), 89 (Ergot Alkaloids)
Heterogeneity: Chi2 = 2.78, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.77 (P = 0.44)
0.001 0.01 0.1 1 10 100 1000
Favours Syntometrine Favours Ergots
Analysis 17.11. Comparison 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental
delivery, Outcome 11 Manual removal of the placenta.
Review: Prophylactic oxytocin for the third stage of labour
Comparison: 17 Oxytocin + ergometrine versus ergot alkaloids alone (given before placental delivery
Outcome: 11 Manual removal of the placenta
Study or subgroup Syntometrine Ergot Alkaloids Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bonham 1963 5/391 5/416 37.7 % 1.06 [ 0.31, 3.65 ]
Soiva 1964 8/560 8/560 62.3 % 1.00 [ 0.38, 2.65 ]
Total (95% CI) 951 976 100.0 % 1.02 [ 0.48, 2.20 ]
Total events: 13 (Syntometrine), 13 (Ergot Alkaloids)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
0.1 0.2 0.5 1 2 5 10
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F E E D B A C K
Pastrana, March 2007
Summary
It is important to take care that the conclusions are based on pre-specified objectives, as sometimes the study is done and then the
objectives decided afterwards.
In this review, there is no discussion of the way different studies determined blood loss, and the limitations of these methods. This
is especially true for Pierre 1992. Also, the results should take into account Hoffman 2004, comparing oxytocin with expectant
management. In this study, although themean change in haematocrit was significantly less in the oxytocin group, there was no difference
in the incidence of postpartum haemorrhage.
(Summary of comment from Jose Luis Pastrana, March 2007)
Reply
A reply from the authors will be published as soon as it is available.
Contributors
Feedback: Jose Luis Pastrana
WH A T ’ S N E W
Last assessed as up-to-date: 30 November 2004.
Date Event Description
1 October 2009 Amended Search updated. Ten reports added to Studies awaiting classification
H I S T O R Y
Protocol first published: Issue 4, 1999
Review first published: Issue 4, 2001
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Date Event Description
20 September 2008 Amended Converted to new review format.
1 March 2007 Feedback has been incorporated Feedback added from Pastrana, March 2007.
1 December 2004 New search has been performed Search updated. We identified 16 new studies; however, none fulfilled the
inclusion criteria
C O N T R I B U T I O N S O F A U T H O R S
The protocol was developed by Diana Elbourne, with Walter Prendiville and Sue McDonald. For the review, Diana Elbourne identified
the potentially relevant papers. Diana Elbourne and Walter Prendiville independently extracted data from the papers, and compared
and agreed the results. Diana Elbourne wrote the first draft of the text and revised it following comments from Guillermo Carroli,
Juliet Wood, Walter Prendiville and Sue McDonald.
The December 2004 update was prepared by Amanda Cotter, AmenNess and Jorge Tolosa, who independently assessed the new papers,
compiled and agreed the results. Amanda Cotter and Jorge Tolosa reread the review and its objectives which they elected to keep.
D E C L A R A T I O N S O F I N T E R E S T
None known.
N O T E S
Pastrana, March 2007
Summary
It is important to take care that the conclusions are based on pre-specified objectives, as sometimes the study is done and then the
objectives decided afterwards.
In this review, there is no discussion of the way different studies determined blood loss, and the limitations of these methods. This
is especially true for Pierre 1992. Also, the results should take into account Hoffman 2004, comparing oxytocin with expectant
management. In this study, although themean change in haematocrit was significantly less in the oxytocin group, there was no difference
in the incidence of postpartum haemorrhage.
(Summary of comment from Jose Luis Pastrana, March 2007)
Reply
A reply from the authors will be published as soon as it is available.ContributorsFeedback: Jose Luis Pastrana.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Oxytocics; ∗Oxytocin; Ergot Alkaloids; Labor Stage, Third [∗drug effects]; Maternal Mortality; Postpartum Hemorrhage [mortality;
∗prevention & control]
MeSH check words
Female; Humans; Pregnancy
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